NEWS & RESOURCES
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
Underlying proof of rejuvenative healing indicative of airway remodeling corresponds with clinical efficacy and improved quality of life Boston, MA—Oct 8, 2024: /PRNewswire/ -- CSA Medical, Inc., a leader in developing spray cryotherapy solutions for the treatment of...
CSA Medical Raises $53 Million in Series D Financing to Support PMA of the RejuvenAir System
TVM Capital Life Science and Yonjin Venture co-led the round, joined by a strong syndicate of existing investors BOSTON, Sept. 9, 2024 /PRNewswire/ -- CSA Medical Inc., developer of The RejuvenAir® System, a Breakthrough Medical Device advancing the power of liquid...
First Randomized Controlled Study with RejuvenAir for Chronic Bronchitis shows Clinically Significant Results
Metered Cryospray treats damaged airways enabling a rejuvenative healing response BOSTON, Sept. 6, 2022 /PRNewswire/ -- CSA Medical, Inc., today announced results from the first randomized, controlled study of Metered Cryospray (MCS) utilizing the RejuvenAir® System...
CSA Medical, Inc. Announces Cooper University Health Care is the 20th Clinical Site to Join the SPRAY-CB Pivotal Study for the treatment of Chronic Bronchitis
Wissam Abouzgheib, MD, chief of pulmonary medicine at Cooper University Health Care, Camden, New Jersey, has joined the SPRAY-CB Study investigating a new device treatment for COPD with Chronic Bronchitis.
CSA Medical Announces Enrollment Milestone in a Mechanism of Action Study utilizing the RejuvenAir® System for COPD Patients with Chronic Bronchitis
Professor Pallav Shah, M.D., F.R.C.P. from the Royal Brompton, London, is principal investigator of a 32 patient study, characterizing the mechanism of action of Metered Cryospray (MCS) with the RejuvenAir System in patients with Chronic Bronchitis.
CSA Medical Announces New Scientific Data Utilizing Metered Cryospray with the RejuvenAir® System for the Treatment of Chronic Bronchitis
Research reveals rejuvenative changes in cellular populations indicative of airway remodeling correspond with clinical efficacy and improved quality of life BOSTON, Sept. 16, 2024 /PRNewswire/ --CSA Medical, Inc., today announced multiple presentations at the European...
CSA Medical Announces 500th Metered CryoSpray Procedure for the Treatment of Chronic Bronchitis
The RejuvenAir System is a minimally invasive medical device therapy which aims to target the underlying cause of COPD with Chronic Bronchitis BOSTON, Feb. 7, 2024 /PRNewswire/ -- CSA Medical Inc., a developer of medical devices advancing the power of liquid nitrogen...
CSA Medical Announces Completion of Enrollment in Mechanism of Action Study utilizing the RejuvenAir® System for COPD Patients with Chronic Bronchitis
All subjects have been enrolled in the RejuvenAir System study Characterizing the Mechanism of Action of Metered Cryospray for the Treatment of Patients with Chronic Obstructive Pulmonary Disease with Chronic Bronchitis.
CSA Medical Announces Metered Cryospray with the RejuvenAir® System for the treatment of Chronic Bronchitis Featured at the 21st World Congress of Bronchology and Interventional Pulmonology
CSA Medical, Inc., today announced metered cryospray utilizing the RejuvenAir® System for the treatment of Chronic Bronchitis was featured in multiple presentations at the 21st World Congress of Bronchology and Interventional Pulmonology in Shanghai
CSA Medical Announces First Procedure in the SPRAY-CB Pivotal Trial for the Treatment of Chronic Bronchitis
CSA Medical Announces First Procedure in the SPRAY-CB Pivotal Trial for the Treatment of Chronic Bronchitis. The SPRAY-CB trial marks the first pivotal study of a medical device therapy targeting the underlying cause of Chronic Bronchitis.
131 Hartwell Avenue
Lexington
Massachusetts 02421
CAUTION: Investigational device. Limited by Federal law to investigational use.
